TScan Therapeutics (NASDAQ:TCRX) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of TScan Therapeutics (NASDAQ:TCRX) from a hold rating to a sell rating in a research report report published on Saturday.

A number of other research analysts have also recently issued reports on TCRX. Wedbush increased their target price on shares of TScan Therapeutics from $4.00 to $5.00 and gave the company an “outperform” rating in a report on Thursday, March 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Thursday, January 22nd. Finally, Morgan Stanley cut TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a report on Friday, November 14th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $6.00.

TScan Therapeutics Stock Performance

NASDAQ:TCRX opened at $1.05 on Friday. The firm’s fifty day simple moving average is $1.08 and its 200-day simple moving average is $1.37. The company has a quick ratio of 8.41, a current ratio of 8.41 and a debt-to-equity ratio of 0.26. The stock has a market cap of $59.59 million, a PE ratio of -1.05 and a beta of 1.03. TScan Therapeutics has a fifty-two week low of $0.88 and a fifty-two week high of $2.57.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Wednesday, March 4th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.09. The firm had revenue of $2.57 million during the quarter, compared to analysts’ expectations of $2.44 million. TScan Therapeutics had a negative net margin of 1,256.81% and a negative return on equity of 79.36%. Analysts expect that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other TScan Therapeutics news, major shareholder Lynx1 Capital Management Lp bought 80,069 shares of the business’s stock in a transaction on Friday, December 19th. The stock was bought at an average price of $0.90 per share, for a total transaction of $72,062.10. Following the completion of the transaction, the insider owned 7,937,416 shares in the company, valued at approximately $7,143,674.40. The trade was a 1.02% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders have bought 161,801 shares of company stock worth $145,621. Company insiders own 4.35% of the company’s stock.

Institutional Trading of TScan Therapeutics

Several large investors have recently modified their holdings of TCRX. Panagora Asset Management Inc. purchased a new position in shares of TScan Therapeutics during the 4th quarter worth approximately $25,000. Catalyst Funds Management Pty Ltd purchased a new stake in TScan Therapeutics in the 2nd quarter valued at approximately $26,000. HRT Financial LP purchased a new stake in TScan Therapeutics in the 4th quarter valued at approximately $26,000. Quadrature Capital Ltd acquired a new stake in TScan Therapeutics during the 2nd quarter valued at $33,000. Finally, Boothbay Fund Management LLC grew its holdings in TScan Therapeutics by 50.0% during the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock valued at $35,000 after buying an additional 8,121 shares during the last quarter. 82.83% of the stock is currently owned by institutional investors and hedge funds.

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.